STERLINBIO

Sterling Biotech Limited has informed the Exchange regarding the outcome of Annual General Meeting of the members of the company held on June 02, 2008.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Sterling_Outcomeofagm_02062008.zip target=NEW> For more details click here.</a>

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 26903.61 lacs for quarter ending on 31-MAR-2008 against Rs. 17403.29 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 5508.86 lacs for the quarter ending on 31-MAR-2008 against Rs. 3805.62 lacs for the quarter ending on 31-MAR-2007.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended on December 31, 2007 will be held on June 02, 2008. Further the Company has informed that the Register of Members and Share Transfer Books of the Company will remain closed from May 26, 2008 to June 02, 2008 (both days inclusive) for the purpose of payment of Dividend for the financial year ended on December 31, 2007 @ 50% per equity share of Re. 1/- each recommended by the Board of Directors of the Company at their meeting held on March 31, 2008 subject to confirmation of members at

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 91084.76 lacs for year ending on 31-DEC-2007 against Rs. 60585.36 lacs for the year ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 18370.53 lacs for the year ending on 31-DEC-2007 against Rs. 13479.6 lacs for the year ending on 31-DEC-2006.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 25129.52 lacs for quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 4931.66 lacs for the quarter ending on 31-DEC-2007.

Sterling Biotech Limited has informed the Exchange that the Board, at its meeting held on March 31, 2008 has recommended 50% (Rs.0.50 per equity share of FV of Rs.1/-) dividend on the equity shares for the financial year ended December 31, 2007 subject to approval of the members.

Sterling Biotech Limited has informed the Exchange that: "The following companies are now part of the Promoters Group of Sterling Biotech Limited ("the Company") with effect from March 28, 2008 as detailed below: 1) Eminence Trading Pvt. Ltd. holds 19,19,000 Equity shares (representing 0.84% of the Company). 2) Antariksha Securities Pvt. Ltd. holds 19,50,000 equity shares (representing 0.85% of the Company). 3) Marut Apparels Pvt. Ltd. holds 18,85,000 equity shares (representing 0.82% of the Company). With the above. promoters group shareholding stands at 8,90,34,694 equity shares of Rs.1/- ea

Sterling Biotech Limited has informed the Exchange that: The following Companies are now part of the Promoters Group of Sterling Biotech Limited with effect from March 27, 2008 as detailed below: (1) Swadeshi Finvest Pvt. Ltd. holds 15,38,000 equity shares (representing 0.67% of Sterling Biotech Equity Capital). (2) Sealord Erections Pvt. Ltd. holds 18,70,000 equity shares (representing 0.81% of Sterling Biotech Equity Capital). (3) Antariksha Capital and Finance (India) Pvt. Ltd. holds 19,00,000 equity shares (representing 0.83% of Sterling Biotech Equity Capital).With the above companies now

Sterling Biotech Limited has informed the Exchange that Extra Ordinary General Meeting of members of the company was held on March 05, 2008. The members of the company have unanimously passed the Special Resolutions for the following business: (1). Re-appointment of Shri Nitin J Sandesara as Managing Director of the Company for 5 years upto February 28, 2013.(2). Enabling resolution for Sponsored ADR, GDR. FCCB, etc to the extent of USD250 Million.(3). Enabling resolution for Issue of ADR, GDR, FCCB, etc. to the extent of USD250 Million.

Sterling Biotech Limited has informed the Exchange regarding the outcome of Board Meeting of the company held on February 07, 2008. The details of the business transacted at the Board Meeting shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Sterling_OutcomeBm_07022008.zip target=NEW> For more details click here.</a>

Sterling Biotech Limited has informed the Exchange that the company will publish Audited Results for the financial year instead of publishing unaudited quarterly results for the quarter ended on December 31, 2007. The Audited Results will be considered and published within the time limits.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 24845.64 lacs for quarter ending on 30-SEP-2007 against Rs. 16096.89 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 4983.23 lacs for the quarter ending on 30-SEP-2007 against Rs. 3643.64 lacs for the quarter ending on 30-SEP-2006.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-JUN-2007 as follows: Net Sales of Rs. 40109.6 lacs for half year ending on 30-JUN-2007 against Rs. 27659.04 lacs for the half year ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 8634.23 lacs for the half year ending on 30-JUN-2007 against Rs. 6084.13 lacs for the half year ending on 30-JUN-2006.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 22706.31 lacs for quarter ending on 30-JUN-2007 against Rs. 14271.34 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4828.61 lacs for the quarter ending on 30-JUN-2007 against Rs. 3060.59 lacs for the quarter ending on 30-JUN-2006.

Sterling Biotech Limited has informed the Exchange regarding the issue of Foreign Currency Convertible Bonds due 2012 (FCCB due 2012). The company has further informed the Exchange that it has issued the FCCBs aggregating to US$ 250 million and the same have been listed on the Singapore Stock Exchange.

Sterling Biotech Limited has informed the Exchange that the members of the Company in their 21st Annual General Meeting held on May 12, 2007 have transacted the following: (1) Declared a Dividend at the rate of 50% (Rs.0.50 per share of Rs.1/- each) for the year ended December 31, 2006. (2) Re-appointed Shri. R.B. Dixit as Director of the Company. (3) Re-appointed Shri. Vilas Joshi as Director of the Company. (4) Re-appointed M/s. H.S.Hathi & Co., Chartered Accountant as Auditors of the Company to hold office until the conclusion of next Annual General Meeting. (5) Passed Special Resolution fo

Sterling Biotech Limited has informed the Exchange that " We have issued Zero Percentage Foreign Currency Convertible Bonds due 2012 aggregating to US$250 million. The Bonds carry a 0% coupon with a yield to maturity of 6.35% per annum and are redeemable in 2012 i.e. after 5 years and 1 day from closing date.The Bonds are convertible into equity shares of the Company at any time after 18 June 2007 at a conversion price of Rs. 204.576 (Rupees Two Hundred four and Paisa Five seventy six) per share which represents a premium of 25% to the Volume Weighted Average price. The Bonds are expected to b

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting will be held on May 12, 2007. Further, the Register of Members and Share Transfer Books of the Company will remain closed from May 07, 2007 to May 12, 2007 (both days inclusive) for the purpose of payment of Dividend @ 0.50% per equity share of Re. 1/- each recommended by the Board of Directors of the Company on March 29, 2007 and subject to confirmation of members at the Annual General Meeting of the Company.

Sterling Biotech Limited has informed the Exchange that: "Titanic Investment and Consultants Private Limited holds 12,76,000 equity shares (representing 0.56% equity capital of Sterling Biotech Limited) is now part of the Promoters Group of Sterling Biotech Limited with effect from 30th March, 2007. With this, shareholding of promoters group stands at 7,79,72,694 equity shares, of Rs.1/- each representing 34.51% of equity capital of Sterling Biotech Limited".

Sterling Biotech Limited has informed the Exchange that "the Company has successfully commissioned its Plant for manufacture of 'Co Enzyme Q10' (Co Q10) at its Masar Plant in Vadodara. The facility is an 100% EOU."

Sterling Biotech Limited has informed the Exchange that the Board has recommended 50% (Rs.0.50 per equity shares of FV of Rs.1/-) dividend on the equity shares for the financial year ended 31st December 2006 subject to approval of the members at the ensuing Annual General Meeting of the Company. The Board has also approved on enabling resolution for issue of equity or equity related instruments or any other convertible instrument aggregating up to US$ 300 million, if required in future, as detailed in the resolution. The enabling resolution will be subject to all necessary permissions and app

Sterling Biotech Limited has informed the Exchange that: "We have designated an e-mail id as mentioned below exclusively for the purpose of registering complaints by investors and also take necessary follow-up action: investorscomplain@stergel.com".

Sterling Biotech Limited has informed the Exchange that: "Following Companies are now part of the Promoters Group of Sterling Biotech Limited with effect from 28th February 2007 as detailed below: 1) Coyote Leasing Private Limited holds 16,47,580 equity shares (representing 0.73% of Sterling Biotech equity Capital). 2) Hizin Trading Company Private Limited holds 16,63,450 equity shares (representing 0.74% of Sterling Biotech equity Capital). 3) Soham Proteins Private Limited holds 15,96,384 equity shares (representing 0.71% of Sterling Biotech equity capital). 4) Cielport Management Private Li

Sterling Biotech Limited has informed the Exchange that: "the company will publish Audited Results for the financial year instead of publishing unaudited quarterly results for the quarter ended on 31st December, 2006. The Audited Results will be considered and published within the time limits as prescribed under clause 41 of the Listing Agreement".

Sterling Biotech Limited has informed the Exchange that the Company will acquire gelatin manufacturing facility in China i.e. China Gelatin Limited. This acquisition will be first overseas acquisition by the Company. The Initiative is in line with Sterling's philosophy of focusing on the growth market globally. The acquisition will enable Sterling to tap new Growth Markets in Far East Asia including China. China is amongst major consumers of Gelatin Globally. The transaction will be all cash deal and will be completed upon receipt of all necessary govt. approvals / consents under applicable la

Sterling Biotech Limited has informed the Exchange that the AGM of the members of the company was held on June 26, 2006 to transact the business as set out in the notice sent to all the shareholders of the Company. The members present at the meeting have :- 1) Declare a dividend @50% (Rs.0.50 per equity share of Re.1/- each) for the year ended December 31, 2005. 2) Re-appointed Shri C. J. Sandesara as Director of the Company. 3) Re-appointed Shri P. B. Mehta as Director of the Company. 4) Re-appointed M/s H. S. Hathi & Co., Chartered Accountants as auditors of the Company to hold office until

Sterling Biotech Limited has informed the Exchange that the AGM wil be held on June 26,2006. Further the company has informed the exchange that the Register of Members and Share Transfer Books of the Company will remain closed from June 19,2006 to June 26,2006 (both days inclusive) for the purpose of payment of Dividend recommended by the Board of Directors of the Comapny and subject to confirmation of members at the AGM of the Company.

Sterling Biotech Limited has informed the Exchange that ABN AMRO Bank NV London Branch has sold 5,00,000 shares through NSE and 5,00,000 shares through NSE aggregating to 0.46% the share capital of Sterling Biotech Limited on April 10, 2006. The mode of sale is Secondary Market and the shareholding of ABN AMRO Bank NV after the said sale is 12,271,695 shares aggregating to 5.55% of the share capital of Sterling Biotech Limited.

Sterling Biotech Limited has informed the Exchange that following Companies are now part of the Promoters Group of Sterling Biotech Limited with effect from March 31, 2006 as detailed below:(1) Relique Leasfin Private Limited holds 16,40,458 equity shares (representing 0.74% of Sterling Biotech,s equity capital).(2) Tarana Exports Private Limited 16,46,422 equity shares (representing 0.74% of Sterling Biotech,s equity capital). With the above companies now being part of the promoters group, shareholding of promoters group stands at 7,02,21,980 equity shares of Rs.1 each representing 31.73% equ

Sterling Biotech Limited had informed the Exchange regarding the signing of Memorandum of Understaking with Torrent Gujarat Biotech Limited, to purchase the manufacturing facility at Vilage : Masar, Dist. : Baroda, Gujarat, as an asset sale, for a consideration of Rs.55 crores, in all cash deal. The Company has now informed the Exchange that the above transaction has been consummated on March 30, 2006.

Sterling Biotech Limited has informed the Exchange that the board in its meeting held on March 28, 2006 has recommended dividend @ 50% on the equity share capital (i.e Rs. 0.50 per equity share of face value of Rs.1.00) of the company for the year ended December 31,2005. The Payment of Dividend is subject to the approval of the Members at the Annual General Meeting of the Company.

Sterling Biotech Limited has informed the Exchange that ABN AMRO Bank NV has acquired 9,029,573 shares aggregating to 4.32% of the share capital of Sterling Biotech Limited on October 03, 2005. The mode of acquisition is Convertible Bonds getting converted into Equity shares and the shareholding of ABN AMRO Bank NV after the said acquisition is 15,916,351 shares aggregating to 7.61% of the share capital of Sterling Biotech Limited.

Citibank N.A. had vide letter dated September 12, 2005, informed the Exchange that ABN AMRO Bank NV London Branch was holding 17,054,508 shares aggregating to 8.90% of the paid up capital of Sterling Biotech Limited. Citibank N.A. has now informed the Exchange that they would like to withdraw the above disclosure since the FCCB conversion request placed by the client was rejected by the global depository, on account of which the holdings never crossed 5%. Further, ABN AMRO Bank NV, London Branch has undertaken a fresh conversion of bonds on October 03, 2005, which has resulted in their holdin

Sterling Biotech Limited has informed the Exchange that the company has entered into a memorandum of understanding with Torrent Gujarat Biotech Limited to purchase the manufacturing facility at Masar,Dist.Baroda,Gujarat,as an asset sale,for a consideration of Rs.55 crores,in an all cash deal.

Sterling Biotech Limited has informed the Exchange that shareholders at their EGM held on October 11, 2005, passed following enabling resolutions: 1) Authorizing Board u/s. 81(1)(A) of the Companies Act, 1956 for issue of Equity Shares / Warrants and / or any instrument convertible into Equity Shares, Global Depository Receipts (GDRs) / American Depository Receipts (ADRs) / FCCBs for an aggregate sum of US$ 50 million. 2) Authorizing Company / Board to borrow up to Rs.3000 crores as and when required, u/s. 293(1)(d) of the Companies Act, 1956 and 3) Authorizing Company / Board to charge the as

Sterling Biotech Limited has informed the Exchange that the Company have completed issue of US$ 140 Million FCCBs due 2010. The Bonds will bear interest at the rate of 0.50% p.a. payable annually. The Conversion Price of the Bonds is determined at Rs.184.8694, about 24% premium to the Closing Price on pricing date. Other terms of the Bonds are as mentioned in the Offering Circular. The Bonds are listed on the Singapore Exchange Limited. Barclays Capital was the Lead Manager, Sole Book-runner and underwriter.

Sterling Biotech Limited has informed the Exchange that Board of Directors at their meeting held on September 16, 2005 decided, To convene an EGM of members on October 11, 2005. The EGM of the shareholder will consider passing enabling resolutions authorizing Board u/s 81(1) (A) of the Companies Act, 1956 for issue of Equity Shares / Warrants and / or any instrument convertible into Equity Shares, Global Depository Receipts (GDRs) / American Depository Receipts (ADRs) / FCCBs for an aggregate sum of US$ 50 million and authorizing the company to borrow up to Rs. 3000 crores in future as and wh

Citibank N.A. has informed the Exchange that ABN AMRO Bank NV London Branch has acquired 9,387,970 shares aggregating to 4.90% of the total paid up capital of Sterling Biotech Limited on September 09, 2005. The mode of acquisition is Convertible Bonds getting converted into Equity shares and the shareholding of ABN AMRO Bank NV London Branch after the said acquisition is 17,054,508 shares aggregating to 8.90% of the total paid up capital of Sterling Biotech Limited.

Sterling Biotech Limited has informed the Exchange that the Company have issued US$ 140 million in Foreign Currency Convertible Bonds, Further, the Lead Manager has an option to subscribe for up to an additional US$ 35 million principal amount of Bonds. The Bonds are convertible into the Ordinary Shares of the Company. The Bonds carry a 0.50% coupon payable annually with an YTM of 6.45% and are redeemable after 5 years and 1 day from closing date (expected to be the September 29, 2005). The Bonds are convertible into equity shares of the Company at any time after November 09, 2005 at a conver

Clarification of News : The press had reports that Sterling Biotech Limited has taken controlling stake in Narmada Gelatine, part of Dubai-based Jumbo group of companies. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Sterling Biotech Limited has vide its letter inter-alia stated, "We hereby deny the news matter relating to acquisition of Narmada Gelatin".

Sterling Biotech Limited has informed the Exchange that the AGM of the members of the company was held on June 27, 2005.The members present at the meeting have: 1) Approved and adopted the Audited Accounts of the company for the year ended December 31, 2004. 2) Declared a Dividend at the rate of 30% (Rs.0.30 per share of Rs.1/- each) for the year ended December 31, 2004. 3) Re-appointed Shri. N.B. Patel as Director of the Company. 4) Re-appointed Shri. R.B. Dixit as Director of the Company. 5) Re-appointed M/s. H.S. Hathi & Co., Chartered Accountants as Auditors of the Company to hold office u

Sterling Biotech Limited has informed the Exchange that the BODs in their meeting held on June 01, 2005 decided: 1)To issue 54,18,432 equity shares of Rs.1/- each at a price of Rs.83.05 to the promoters of the company by way of preferential offer on firm allotment basis subject to approval of shareholder. 2)To convene the AGM for the F.Y. ending December 31, 2004 on June 27,2005. 3)To close register of members and share transfer books (book closure) from June 21, 2005 to June 27, 2005 (inclusive of both days) for payment of dividend for the year ending on December 31, 2004, subject to approval

Sterling Biotech Limited has informed the Exchange that the Board at its meeting held on April 30, 2005, have recommended a dividend @ 30% on equity shares i.e. Rs.0.30 on equity shares of Re.1/- each, for the FY ended on December 31, 2004 subject to the approval of the Members at the AGM of the Company.

Sterling Biotech Limited had informed the Exchange regarding the Company's raising of US $ 70mn and the Additional FCCB ("the additional said FCCB") of US $ 20mn.The company has now informed that the allotment pertaining to the said additional FCCB is now complete. The said FCCB is fungible with the B Bonds issued earlier hence, all other terms remain same except that the share issued will be of Face value of Rs.1/-. The FCCB are also expected to be listed on the Luxembourg Stock Exchange.

Sterling Biotech Limited has informed the Exchange that in pursuance to the resolution passed at the EGM of the members of the company held on March 05,2005 to consider sub-division of one equity shares of face value of Rs.2/- each to two equity shares of face value of Rs.1/- each, the BODs of the company have fixed a record date for the sub-division of shares from face value of Rs.2/- each to face value of Rs.1/- each on March 25,2005.

Sterling Biotech Limited has informed the Exchange that the record date for sub-division of shares from Rs.2/- face value to Rs.1/- face value, has been changed to March 26, 2005 instead of March 25, 2005.

Sterling Biotech Limited has informed the Exchange that at the meeting of the BOD's of the Company held on February 07, 2005, the BOD's have decided to split the equity shares of face value of Rs.2/- each in to face value of Re.1/- each subject to approval of members at General Meeting of the Company. An EGM of members of the Company will be held on March 05, 2005 to consider split of shares in to face value of Re.1/- each and alteration of Capital Clause of Memorandum of Association of the Company.

Sterling Biotech Limited has informed the Exchange that in pursuance of special resolution passed at the AGM of the company held on June 25, 2004 vide SEBI (Delisting of securities) Guidelines, 2003, The Delhi Stock Exchange Association Limited has confirmed the delisting of the company's shares w.e.f. October 13, 2004.

Sterling Biotech Limited has informed the Exchange that the company has raised an additional US$ 20 Million FCCB besides US$ 70 Million raised earlier i.e. total of US$90 Million FCCB. The Bonds are convertible into either the Ordinary Shares of the company or GDSs each representing 6 Ordinary Shares of the company, at the option of the Bond holders. The Bonds will be issued in 2 Tranches: Tranche A aggregating US$ 20 million and Tranche B aggregating US$ 70 million. Both Tranche A and Tranche B Bonds carry a 2% coupon payable semi annually, Tranche A Bonds will be redeemable at a premium of